This invention is directed to novel central nervous system depressants of Formula I ##STR1## wherein R.sup.1 is selected from the group consisting of (lower)alkyl and ar(lower)alkyl; R.sup.2 is selected from the group consisting of di(lower)alkylamino(lower)alkyl and diaryl(lower)alkylamino(lower)alkyl; R.sup.1 and R.sup.2 may be concatenated to form a radical selected from the group consisting of ##STR2## wherein R.sup.4 is selected from the group consisting of (lower)alkyl, aryl, hydroxy(lower)alkyl, ar(lower)alkyl and (lower)alkoxy(lower)alkyl; R.sup.5 is selected from the group consisting of (lower)-alkylamino and piperidino; n is an integer from 3 to 5; m is an integer from 1-2; r is an integer from 2 to 3; s is an integer from 0 to 6; t is an integer from 0-6; with the proviso that the sum of s and t is 3 to 6; R.sup.3 is selected from the group consisting of hydrogen, (lower)alkyl, ar(lower)alkyl and (lower)alkoxy(lower)alkyl; X is selected from the group consisting of halogen, cyano, trifluoromethyl, nitro and (lower)alkylthio; Y is selected from the group consisting of hydrogen, halogen, trifluoromethyl, nitro and (lower)alkylthio; and the pharmaceutically acceptable salts thereof, in addition to the method of their preparation and administration and administrable compositions containing the active compounds.
Drawings
Claims12
A compound selected from the group consisting of ##STR45## wherein R.sup.1 is a member selected from the group consisting of alkyl of 1 to 6 carbon atoms and hydrocarbyl aralkyl of 7 to 16 carbon atoms;
R.sup.2 is a member selected from the group consisting of dialkylaminoalkyl of 3 to 18 carbon atoms, and hydrocarbyl diaralkylaminoalkyl of 14 to 32 carbon atoms;
R.sup.1 and R.sup.2, when taken together form a member selected from the group consisting of ##STR46## wherein R.sup.4 is a member selected from the group consisting of alkyl of 1 to 6 carbon atoms, hydrocarbyl aryl of 6 to 10 carbon atoms, hydroxyalkyl of 1 to 6 carbon atoms, hydrocarbyl aralkyl of 7 to 16 carbon atoms and alkoxyalkyl of 2 to 12 carbon atoms;
R.sup.5 is a member selected from the group consisting of alkylamino of 1 to 6 carbon atoms and piperidino;
n is one of the integers 3, 4 or 5;
m is one of the integers 1 or 2;
r is one of the integers 2 or 3;
s is an integer from 0 to 6;
t is an integer from 0 to 6;
with the proviso that the sum of s and t must be at least 3 and not more than 6;
R.sup.3 is a member selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms, hydrocarbyl aralkyl of 7 to 12 carbon atoms and alkoxy alkyl of 2 to 12 carbon atoms;
X is a member selected from the group consisting of halogen, cyano, trifluoromethyl, nitro and alkylthio of 1 to 6 carbon atoms;
Y is a member selected from the group consisting of hydrogen, halogen, trifluoromethyl, nitro and alkylthio of 1 to 6 carbon atoms;
and the pharmaceutically acceptable salts thereof.
10 more elements
Dependencies are inferred from the claim text.
Serial129,638Parent of this continuation-in-part · filed 30 Mar 1971
US 4,065,451 AThis patent
From the US filing history. Foreign family members aren’t listed.
27 Dec 1994Estimated · howhidePre-1995 term; greater of 17 years from grant or 20 years from filing when eligible. Maintenance-fee lapses, terminal disclaimers and statutory extensions have not been checked. The continuity chain may be incomplete; this is not an enforceability determination.
USPTO file history isn’t available for this patent, so only indexed dates are shown.
Description2,976 words
Summary1,094 words
#This invention relates to the pharmacologically active 1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one, substituted diamino acetates. The chemical structure of these compounds may be schematically represented by Formula I: ##STR3## wherein R.sup.1 is selected from the group consisting of (lower)alkyl and ar(lower)alkyl; R.sup.2 is selected from the group consisting of di(lower)alkylamino(lower)alkyl and diar(lower alkylamino(lower)alkyl; R.sup.1 and R.sup.2 may form a radical selected from the group consisting of ##STR4## wherein R.sup.4 is selected from the group consisting of (lower)alkyl, aryl, hydroxy(lower)alkyl, ar(lower)alkyl and (lower)alkoxy(lower)alkyl; R.sup.5 is selected from the group consisting of (lower)alkylamino and piperidino; n is an integer from 3-5; m is an integer from 1-2; r is an integer from 2 to 3; s is an integer from 0-6; t is an integer from 0-6; with the proviso that the sum of s and t must be 3,4,5 or 6; R.sup.3 is selected from the group consisting of hydrogen, (lower)alkyl, ar(lower)alkyl and (lower)alkoxy(lower)alkyl; X is selected from the group consisting of halogen, cyano, trifluoromethyl, nitro and (lower)alkylthio; Y is selected from the group consisting of hydrogen, halogen, trifluoromethyl, nitro and (lower)alkylthio; and the pharmaceutically acceptable salts thereof. The hydrated forms of formula I are also within the scope of the invention, the anhydrous and various hydrated forms of each compound being readily prepared by drying the initially formed product.
#The term (lower)alkyl is used to include straight and branched chain hydrocarbon groups which contain from one to about six carbon atoms such as methyl, ethyl, i-propyl, n-propyl, n-butyl, n-hexyl and the like. The term (lower)alkoxy is used to include hydrocarbonoxy groups which contain from one to about six carbon atoms such as methoxy, ethoxy, n-propoxy, n-butoxy, n-penoxy and the like. The terms halo and halogen are used to include atoms selected from the group consisting of chlorine, fluorine, bromine and iodine. The terms aryl and arare used to include monovalent, aromatic, hydrocarbon radicals containing 6 to 10 carbon atoms such as phenyl, tolyl and naphthyl. The term pharmaceutically acceptable acid addition salts is used to include those non-toxic acid addition salts which may be formed with both organic and inorganic acids such as hydrochloric, hydrobromic, sulfuric, phosphoric, methane sulfonic, nitric, p-toluene sulfonic, acetic, citric, maleic, succinic and the like.
#The compounds of the invention may be prepared by the following reaction scheme: ##STR5## wherein R.sup.1, R.sup.2, R.sup.3, X and Y are the same as hereinabove described and Z is selected from the group consisting of chlorine, bromine and iodine.
Detailed description1,882 words
#The following examples are added to illustrate but not to necessarily limit the scope of the invention.
#A mixture of 7-chloro-5-(o-chlorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one, 4-oxide (16 g, 0.05 mole) and chloroacetic anhydride (25 g, 0.145 mole) was heated with stirring at 100.degree.-110.degree. for 2.5 hours. Ether was then added and the mixture was stirred for 10 minutes. The solid obtained (14.7 g, 75% yield) was filtered, washed with ether and recrystallized from dichloromethane-ether, mp. 232.degree.-234.degree., nmr (DMSO-D.sub.6) ppm (.delta.); 4.72 (s, 2); 6.10 (s, 1); 7.17 (d, 1); 7.4-8 (m, 6).
#Anal. Calcd for C.sub.17 H.sub.11 Cl.sub.3 N.sub.2 O.sub.3 : C, 51.35; H, 2.79; N, 7.05. Found: C, 51.26; H, 2.83; N, 6.94.